These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12594287)

  • 1. Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias.
    Woodberry T; Gardner J; Elliott SL; Leyrer S; Purdie DM; Chaplin P; Suhrbier A
    J Immunol; 2003 Mar; 170(5):2599-604. PubMed ID: 12594287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).
    Jayakumar A; Castilho TM; Park E; Goldsmith-Pestana K; Blackwell JM; McMahon-Pratt D
    PLoS Negl Trop Dis; 2011 Jun; 5(6):e1204. PubMed ID: 21695103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models.
    Dégano P; Schneider J; Hannan CM; Gilbert SC; Hill AV
    Vaccine; 1999 Nov; 18(7-8):623-32. PubMed ID: 10547421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
    Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
    J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
    Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule.
    Gherardi MM; Pérez-Jiménez E; Nájera JL; Esteban M
    J Immunol; 2004 May; 172(10):6209-20. PubMed ID: 15128809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice.
    Bråve A; Boberg A; Gudmundsdotter L; Rollman E; Hallermalm K; Ljungberg K; Blomberg P; Stout R; Paulie S; Sandström E; Biberfeld G; Earl P; Moss B; Cox JH; Wahren B
    Mol Ther; 2007 Sep; 15(9):1724-33. PubMed ID: 17579577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.
    Altenburg AF; van de Sandt CE; van Trierum SE; De Gruyter HLM; van Run PRWA; Fouchier RAM; Roose K; Saelens X; Volz A; Sutter G; de Vries RD; Rimmelzwaan GF
    J Virol; 2016 Nov; 90(22):10209-10219. PubMed ID: 27581985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prime-boost vaccinations using recombinant flavivirus replicon and vaccinia virus vaccines: an ELISPOT analysis.
    Rattanasena P; Anraku I; Gardner J; Le TT; Wang XJ; Khromykh AA; Suhrbier A
    Immunol Cell Biol; 2011 Mar; 89(3):426-36. PubMed ID: 20680025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified-vaccinia-virus-Ankara (MVA) priming and fowlpox-virus booster elicit a stronger CD8+ T-cell response in mice against an HIV-1 epitope than does a DNA/poxvirus prime-booster approach.
    Vázquez-Blomquist D; Quintana D; Duarte CA
    Biotechnol Appl Biochem; 2004 Jun; 39(Pt 3):313-8. PubMed ID: 15154843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules.
    Eo SK; Gierynska M; Kamar AA; Rouse BT
    J Immunol; 2001 May; 166(9):5473-9. PubMed ID: 11313385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1.
    Lambe T; Carey JB; Li Y; Spencer AJ; van Laarhoven A; Mullarkey CE; Vrdoljak A; Moore AC; Gilbert SC
    Sci Rep; 2013; 3():1443. PubMed ID: 23485942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens.
    Tan WG; Zubkova I; Kachko A; Wells F; Adler H; Sutter G; Major ME
    PLoS One; 2017; 12(7):e0181578. PubMed ID: 28732046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis.
    Pérez-Jiménez E; Kochan G; Gherardi MM; Esteban M
    Microbes Infect; 2006 Mar; 8(3):810-22. PubMed ID: 16504562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers.
    Pinto AR; Fitzgerald JC; Giles-Davis W; Gao GP; Wilson JM; Ertl HC
    J Immunol; 2003 Dec; 171(12):6774-9. PubMed ID: 14662882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania.
    Dondji B; Deak E; Goldsmith-Pestana K; Perez-Jimenez E; Esteban M; Miyake S; Yamamura T; McMahon-Pratt D
    Eur J Immunol; 2008 Mar; 38(3):706-19. PubMed ID: 18286565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
    Park JY; Jin DH; Lee CM; Jang MJ; Lee SY; Shin HS; Chung YH; Kim KY; Kim SS; Lee WB; Shin YK; Lee WJ; Park YM; Kim D
    J Immunother; 2010 Jun; 33(5):510-22. PubMed ID: 20463596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity.
    Someya K; Xin KQ; Matsuo K; Okuda K; Yamamoto N; Honda M
    J Virol; 2004 Sep; 78(18):9842-53. PubMed ID: 15331719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.